Triveni Bio
Triveni Bio raises $115M Series B at $550M valuation
Quick Facts
Triveni Bio: Series B Funding Round
Triveni Bio has successfully raised $115M in Series B funding, reaching a valuation of $550M.
Company Overview
Advancing preclinical antibody programs for immunological disorders
Funding Details
The Series B round was led by Lightspeed Venture Partners, with participation from GV.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Employees: 85+
- Category: Biotech
Investment
Triveni Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Lightspeed Venture Partners: Verified investor in Series B
- GV: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
